Sign in
Taking peoplePhase 1/2

Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury

Key facts

Who runs it
Centre Hospitalier Universitaire de Nīmes
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
14 people, planned
Started
4 Jun 2026
Expected to end
Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Continuous veino-veinous dialysis with iron-chelator supplemented dialysate
Record updated
5 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adult patients (≥18 years) admitted to ICU with sepsis-associated AKI requiring CRRT
  • Sepsis defined according to SEPSIS-3 criteria (suspected/documented infection with organ dysfunction indicated by ≥2-point increase in SOFA [Sequential Organ Failure Assessment] score)
  • AKI Stage 3 per KDIGO (Kidney Disease: Improving Global Outcomes) criteria: acute rise in serum creatinine ≥3 times baseline or serum creatinine ≥4 mg/dL or urine output <0.3 mL/kg/h for ≥24 hours or anuria (urine output <100ml) for ≥12 hours
  • Indications for CRRT: refractory hyperkalemia (>6 mmol/L) or refractory metabolic acidosis (pH < 7.20) or acute pulmonary edema unresponsive to medical management or urine output <0.3 ml/kg/hour or anuria (urine output <100ml) persistent for 48 hours and refractory to medical treatment
  • Informed consent obtained from patient or legal representative
  • Affiliated with or beneficiary of a health insurance plan

Who cannot take part

  • Concurrent participation in another interventional study
  • Known shellfish allergy
  • Moribund status with life expectancy too low to benefit
  • Exclusion period defined by another study
  • Under legal protection (guardianship or curatorship)
  • Inability to obtain informed consent from patient or representative
  • Pregnant, parturient, or breastfeeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the intensive care unit (ICU). The main questions it aims to answer are:

Read full original descriptionShow less

Does adding MEX-CD1 to the dialysis fluid increase the amount of iron removed during dialysis? Is using MEX-CD1 in dialysis fluid safe for patients?

Participants will:

Be adults in the ICU with sepsis-associated AKI who need continuous dialysis (renal replacement therapy) Receive two 24-hour dialysis sessions: one with standard dialysis fluid and one with dialysis fluid containing MEX-CD1 Serve as their own control, meaning they will receive both treatments

Researchers will measure:

The amount of iron removed in the dialysis waste fluid (primary outcome) Blood levels of iron Changes in other trace elements Markers of inflammation and oxidative stress Safety outcomes up to 28 days after treatment This is a pilot study being done at a single hospital in France.

The 2 groups in the trial

  • Sequence A: MEX-CD1-supplemented dialysate first, then standard dialysateOther group

    Participants will receive two consecutive 24-hour CVVHD sessions using: * Standard Dialysate: Commercially available CiCa™ dialysate (Fresenius Medical Care, Germany) * MEX-CD1 Dialysate: CiCa™ dialysate supplemented with MEX-CD1 at 50 mg/L (28). MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight

    Treatment: Continuous veino-veinous dialysis with iron-chelator supplemented dialysate

  • Sequence B: Standard dialysate first, then MEX-CD1-supplemented dialysateOther group

    Participants will receive two consecutive 24-hour CVVHD sessions using: * Standard Dialysate: Commercially available CiCa™ dialysate (Fresenius Medical Care, Germany) * MEX-CD1 Dialysate: CiCa™ dialysate supplemented with MEX-CD1 at 50 mg/L (28). MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight

    Treatment: Continuous veino-veinous dialysis with iron-chelator supplemented dialysate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Performance and Safety of Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate During Continuous Veno-venous Hemodialysis for Sepsis-associated AKI: Protocol for a Phase I-II Randomized Crossover Pilot Study.
Publications
Record updated
5 June 2026